Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET
Creators
- 1. King's College London, Cancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, London (United Kingdom)
- 2. King's College London, Guy's, Kings and St Thomas' Medical School, London (United Kingdom)
- 3. Guys and St Thomas' NHS Foundation Trust, National Neurofibromatosis Service, Department of Neurology, London (United Kingdom)
Description
Measurement of heterogeneity in 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) images is reported to improve tumour phenotyping and response assessment in a number of cancers. We aimed to determine whether measurements of 18F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs). 18F-FDG PET data from a cohort of 54 patients (24 female, 30 male, mean age 35.1 years) with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. Scans were performed to a standard clinical protocol at 1.5 and 4 h post-injection. Six first-order [including three standardised uptake value (SUV) parameters], four second-order (derived from grey-level co-occurrence matrices) and four high-order (derived from neighbourhood grey-tone difference matrices) statistical features were calculated from tumour volumes of interest. Each patient had histological verification or at least 5 years clinical follow-up as the reference standard with regards to the characterisation of tumours as benign (n = 30) or malignant (n = 24). There was a significant difference between benign and malignant tumours for all six first-order parameters (at 1.5 and 4 h; p < 0.0001), for second-order entropy (only at 4 h) and for all high-order features (at 1.5 h and 4 h, except contrast at 4 h; p < 0.0001-0.047). Similarly, the area under the receiver operating characteristic curves was high (0.669-0.997, p < 0.05) for the same features as well as 1.5-h second-order entropy. No first-, second- or high-order feature performed better than maximum SUV (SUVmax) at differentiating benign from malignant tumours. 18F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters. However, heterogeneity analysis does not improve on SUVmax discriminative performance. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-017-3733-1Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 44
- Journal Issue
- 11
- Journal Page Range
- p. 1845-1852
- ISSN
- 1619-7070
- CODEN
- EJNMA6
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 48091692
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ACCURACY; ALGORITHMS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC USES; FLUORINE 18; FLUORODEOXYGLUCOSE; IMAGE PROCESSING; NEOPLASMS; NERVES; POSITRON COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY; SPECIFICITY; UPTAKE
- Descriptors DEC
- ANTIMETABOLITES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MATERIALS; MATHEMATICAL LOGIC; NANOSECONDS LIVING RADIOISOTOPES; NERVOUS SYSTEM; NUCLEI; ODD-ODD NUCLEI; PROCESSING; RADIOACTIVE MATERIALS; RADIOISOTOPES; TOMOGRAPHY; USES